Subsequent risk coefficient analysis across multiple tumor types revealed a significant positive correlation between elevated Gal-3 levels and poor prognosis/increased clinical risk coefficients in patients with pancreatic cancer, glioma, uveal melanoma, and liver cancer. Here, LGALS3 is linked to central nervous system cancer.